Citation Impact
Citing Papers
The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti–HER-2 Therapy and Personalized Medicine
2009
Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody
2016 Standout
Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3+ Regulatory T Cells (Tregs) in Human Cancers
2018 StandoutNobel
Afucosylated Antibodies Increase Activation of FcγRIIIa-Dependent Signaling Components to Intensify Processes Promoting ADCC
2014
Genome-wide CRISPR screens reveal a specific ligand for the glycan-binding immune checkpoint receptor Siglec-7
2021 StandoutNobel
Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update
2011 Standout
Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
2012 Standout
Revised American Thyroid Association Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer
2009 Standout
Management Guidelines for Children with Thyroid Nodules and Differentiated Thyroid Cancer
2015 Standout
2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer
2015 Standout
Chemotherapy and Targeted Therapy for Women With Human Epidermal Growth Factor Receptor 2–Negative (or unknown) Advanced Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline
2014
CD16 is indispensable for antibody-dependent cellular cytotoxicity by human monocytes
2016
Breast cancer
2019 Standout
Lapatinib and breast cancer: current indications and outlook for the future
2010
Triple-negative breast cancer molecular subtyping and treatment progress
2020 Standout
The immune system and response to HER2-targeted treatment in breast cancer
2014
The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications
2020 Standout
Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update
2018 Standout
Liver Metastases From Breast Cancer: What Role for Surgery? Indications and Results
2017
2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients
2016 Standout
Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial
2009
Marine Natural Products and Related Compounds as Anticancer Agents: an Overview of their Clinical Status
2013
Emerging evidence on the pathobiology of mucositis
2013
Emerging strategies for TNBC with early clinical data: new chemoimmunotherapy strategies
2022
Alternative lengthening of telomeres in mammalian cells
2002
Rechallenging with anthracyclines and taxanes in metastatic breast cancer
2010
Tumor-associated macrophages and anti-tumor therapies: complex links
2016
Macrophages in immunoregulation and therapeutics
2023 Standout
Trastuzumab mediates antibody-dependent cell-mediated cytotoxicity and phagocytosis to the same extent in both adjuvant and metastatic HER2/neu breast cancer patients
2013
Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial
2011 Standout
Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease
2016 Standout
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy
2014 Standout
Current State and Future Perspective of Molecular Diagnosis of Fine-Needle Aspiration Biopsy of Thyroid Nodules
2011
Natural and therapy-induced immunosurveillance in breast cancer
2015
Inhibitors of hypoxia-inducible factor 1 block breast cancer metastatic niche formation and lung metastasis
2012 StandoutNobel
The immune contexture in cancer prognosis and treatment
2017 Standout
Contemporary diagnostic approach to the thyroid nodule
2006
Cancer-associated cachexia
2018 Standout
Inflammation and tumor progression: signaling pathways and targeted intervention
2021 Standout
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2010 Standout
Natural Killer Cell Mediated Antibody-Dependent Cellular Cytotoxicity in Tumor Immunotherapy with Therapeutic Antibodies
2013
Beyond the Suspicious Thyroid Fine Needle Aspirate
2003
Telomere fusion to chromosome breaks reduces oncogenic translocations and tumour formation
2005 StandoutNobel
Emerging evidence on the pathobiology of mucositis
2013
Bisphosphonates in breast cancer
2005
Clinical Validity and Utility of Tumor-Infiltrating Lymphocytes in Routine Clinical Practice for Breast Cancer Patients: Current and Future Directions
2017
Molecular fine-needle aspiration biopsy diagnosis of thyroid nodules by tumor specific mutations and gene expression patterns
2010
Macrophages are critical effectors of antibody therapies for cancer
2015
Preoperative Diagnosis of Benign Thyroid Nodules with Indeterminate Cytology
2012 Standout
Mitochondrial Membrane Permeabilization in Cell Death
2007 Standout
Ruling in or ruling out thyroid malignancy by molecular diagnostics of thyroid nodules
2014
Diagnostic terminology and morphologic criteria for cytologic diagnosis of thyroid lesions: A synopsis of the National Cancer Institute Thyroid Fine‐Needle Aspiration State of the Science Conference
2008 Standout
Tumour-associated macrophages as treatment targets in oncology
2017 Standout
FINE-NEEDLE ASPIRATION BIOPSY OF THE THYROID
2001
Targeting immune effector cells to promote antibody-induced cytotoxicity in cancer immunotherapy
2011
Paradoxical roles of the immune system during cancer development
2006 Standout
Docetaxel and cyclophosphamide as neoadjuvant chemotherapy in HER2-negative primary breast cancer
2016
Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2019 Standout
Molecular alterations in triple-negative breast cancer—the road to new treatment strategies
2016
Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
2011 Standout
MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy
2020 Standout
Glycosylation in cancer: mechanisms and clinical implications
2015 Standout
Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study
2019
Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease During Pregnancy and Postpartum
2011 Standout
Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Taskforce
2006 Standout
2017 Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease During Pregnancy and the Postpartum
2017 Standout
Follicular lesions of thyroid
2000
Practical Approach to Triple-Negative Breast Cancer
2017
Bisphosphonates: Clinical Experience
2004
Emerging drugs for the treatment of triple-negative breast cancer: a focus on phase II immunotherapy trials
2021
Breast Cancer Statistics, 2022
2022 Standout
Marine natural products
2015 Standout
Diversity, Mechanisms, and Significance of Macrophage Plasticity
2019 Standout
Breast Cancer Treatment
2019 Standout
Chemotherapy induces enrichment of CD47 + /CD73 + /PDL1 + immune evasive triple-negative breast cancer cells
2018 StandoutNobel
Precision glycocalyx editing as a strategy for cancer immunotherapy
2016 StandoutNobel
American Association of Clinical Endocrinologists, American College of Endocrinology, and Associazione Medici Endocrinologi Medical Guidelines for Clinical Practice for the Diagnosis and Management of Thyroid Nodules - 2016 Update Appendix
2016 Standout
Clinical Features of Metastatic Bone Disease and Risk of Skeletal Morbidity
2006 Standout
How Shelterin Protects Mammalian Telomeres
2008 Standout
Guidelines for the management of thyroid cancer
2014 Standout
Macrophage plasticity, polarization, and function in health and disease
2018 Standout
Preventing and Managing Toxicities of High-Dose Methotrexate
2016 Standout
Works of K. Aogi being referenced
Lapatinib monotherapy in patients with relapsed, advanced, or metastatic breast cancer: efficacy, safety, and biomarker results from Japanese patients phase II studies
2009
Changes in tumor expression of HER2 and hormone receptors status after neoadjuvant chemotherapy in 21 755 patients from the Japanese breast cancer registry
2015
A phase II study of eribulin in Japanese patients with heavily pretreated metastatic breast cancer
2011
FcγR2A and 3A polymorphisms predict clinical outcome of trastuzumab in both neoadjuvant and metastatic settings in patients with HER2-positive breast cancer
2010
Phase III trial of doxorubicin plus cyclophosphamide (AC), docetaxel, and alternating AC and docetaxel as front-line chemotherapy for metastatic breast cancer: Japan Clinical Oncology Group trial (JCOG9802)
2009
Feasibility Study of Docetaxel with Cyclophosphamide as Adjuvant Chemotherapy for Japanese Breast Cancer Patients
2009
Telomerase activity in lesions of the thyroid: application to diagnosis of clinical samples including fine-needle aspirates.
1998
Telomerase activity in soft-tissue and bone sarcomas.
2000
Abstract S1-07: A phase III trial of adjuvant capecitabine in breast cancer patients with HER2-negative pathologic residual invasive disease after neoadjuvant chemotherapy (CREATE-X, JBCRG-04)
2016
A phase II dose-ranging study of palonosetron in Japanese patients receiving moderately emetogenic chemotherapy, including anthracycline and cyclophosphamide-based chemotherapy
2009
A randomized, double-blind, placebo-controlled phase III trial of zoledronic acid in the prevention of skeletal complications in Japanese women with bone metastases from breast cancer
2004
Differential survival following trastuzumab treatment based on quantitative HER2 expression and HER2:HER2 dimerization in a clinic-based cohort of patients with metastatic breast cancer
2007